|
Two studies
on the acute and neuroprotective effects of Neotrofin™
in animal models of Parkinson's disease demonstrated that
the drug produced an acute improvement in motor function,
according to data presented at the XIVth World Congress of
Pharmacology in San Francisco.
These
pre-clinical studies involving rats support the recently reported
positive preliminary clinical results from a human phase 2
study of Neotrofin in patients with early stages of Parkinson's
disease.
"Neotrofin
protected dopamine neurons both in animal models of Parkinson's
disease and in tissue culture," said David R. Helton,
Director of Behavioral Pharmacology and Toxicology at NeoTherapeutics.
"Dopamine neurons degenerate in patients with Parkinson's
disease, and the models used in these experiments are commonly
used to evaluate drugs for the treatment of Parkinson's disease."
"These
studies represent strong evidence of Neotrofin's potential
as a treatment for Parkinson's disease," said Alvin J.
Glasky, CEO of NeoTherapeutics. "Both the acute and neuroprotective
effects of Neotrofin in these models provide the rationale
for the continued clinical development of this drug in Parkinson's
disease."
Source:
Medical Week staff,
week of July 14, 2002
|
HOME PAGE
